Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.

被引：0
|
作者：
Piedra, A. [1 ]
Barba Joaquin, A. [1 ]
Mosquera Martinez, J. [2 ]
Fernandez Bruno, M. [2 ]
Cordeiro Gonzalez, P. [3 ]
Sullivan, I. G. [1 ]
Riudavets Melia, M. [1 ]
Aguado Sorolla, M. [1 ]
Gallardo Melo, P. [1 ]
Martin Cullell, B. [4 ]
Gavira, J. [1 ]
Tapia, J. C. [1 ]
Romano, A. [1 ]
Bosma, F. [5 ]
Sanchez Del Rio, S. [1 ]
Sanz Beltran, J. [1 ]
Molina Perez, M. A. [6 ]
Serra Lopez, J. [1 ]
Garcia Campelo, M. R. [7 ]
Majem Tarruella, M. [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[2] CHUAC Complexo Hosp Univ A Coruna, Med Oncol Serv Dept, La Coruna, Spain
[3] CHUAC Complexo Hosp Univ A Coruna, Oncol Dept, La Coruna, Spain
[4] Hosp Santa Creu & Sant Pau, Dept Oncol, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Oncol, Barcelona, Spain
[6] Hosp Santa Creu & Sant Pau, Oncol Med, Barcelona, Spain
[7] Inst Invest Biomed A Coruna INIBIC, Dept Med Oncol, La Coruna, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1098P
引用
收藏
页码：S1053 / S1053
页数：1
相关论文
共 50 条
  • [1] PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC
    Jorgensen, Jan Trost
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [2] Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
    Miyakoshi, Jun
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Ohe, Yuichiro
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Suzuki, Takuji
    Ohe, Yuichiro
    LUNG CANCER, 2024, 191
  • [4] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
    Shinobu Hosokawa
    Eiki Ichihara
    Daijiro Harada
    Shoichi Kuyama
    Koji Inoue
    Kenichi Gemba
    Hirohisa Ichikawa
    Yuka Kato
    Naohiro Oda
    Isao Oze
    Tomoki Tamura
    Toshiyuki Kozuki
    Takahiro Umeno
    Toshio Kubo
    Katsuyuki Hotta
    Akihiro Bessho
    Yoshinobu Maeda
    Katsuyuki Kiura
    International Journal of Clinical Oncology, 2022, 27 : 1139 - 1144
  • [5] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
    Hosokawa, Shinobu
    Ichihara, Eiki
    Harada, Daijiro
    Kuyama, Shoichi
    Inoue, Koji
    Gemba, Kenichi
    Ichikawa, Hirohisa
    Kato, Yuka
    Oda, Naohiro
    Oze, Isao
    Tamura, Tomoki
    Kozuki, Toshiyuki
    Umeno, Takahiro
    Kubo, Toshio
    Hotta, Katsuyuki
    Bessho, Akihiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1139 - 1144
  • [6] Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
    Fiorelli, Alfonso
    Vitiello, Fabiana
    Morgillo, Floriana
    Santagata, Mario
    Spuntarelli, Chiara
    Di Domenico, Marina
    Santini, Mario
    Bianco, Andrea
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S618 - S620
  • [7] Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.
    Takumida, Hiroshi
    Horinouchi, Hidehito
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Benchmarking the efficacy and safety of pembrolizumab plus chemotherapy to pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression
    Takumida, H.
    Horinouchi, H.
    Masuda, K.
    Shinno, Y.
    Okuma, Y.
    Yoshida, T.
    Goto, Y.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S855 - S856
  • [9] Predictive factors of response to PD-(L)1 inhibitors in patients with advanced non-small cell lung (NSCLC) and high PD-L1 expression
    Barba Joaquin, A.
    Piedra, A.
    Mosquera, J.
    Riudavets, M.
    Gomez-Randulfe, M. I.
    Garcia Campelo, M. R.
    Sullivan, I. G.
    Serra, J.
    Aguado, M.
    Majem Tarruella, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S768 - S769
  • [10] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
    Itani, H.
    Nigi, A.
    Iwamoto, K.
    Ito, Y.
    Tanigawa, M.
    Kondo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
12345